Insmed Inc

INSM

145.100USD

+2.570+1.80%

Close 09/05, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

8 / 686

Overall Ranking

77 / 4731

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 20 analysts

Buy

Current Rating

150.699

Target Price

+3.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 48.24% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 89.76.

Undervalued

The company’s latest PE is -25.57, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 207.14M shares, decreasing 1.46% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 17.60M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.20.

The company's current financial score is 7.56, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 92.82M, representing a year-over-year increase of 22.94%, while its net profit experienced a year-over-year increase of 63.33%.

Score

Industry at a Glance

Previous score

7.56

Change

0



Financials

9.46

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.22

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.89

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.15

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.08

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -23.71, which is -49.56% below the recent high of -11.96 and 24.02% above the recent low of -18.01.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 8/686

No Data

The company’s current earnings forecast score is 8.63, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Insmed Inc is 140.00, with a high of 240.00 and a low of 99.00.

Score

Industry at a Glance

Previous score

8.60

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.90, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 144.45 and the support level at 114.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.65

Change

0.11

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-05

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 108.81%, representing a quarter-over-quarter decrease of 2.55%. The largest institutional shareholder is The Vanguard, holding a total of 17.60M shares, representing 8.33% of shares outstanding, with 17.84% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Darwin Global Management Ltd

15.40M

+18.81%

The Vanguard Group, Inc.

Star Investors

18.23M

+0.26%

JP Morgan Asset Management

5.41M

+86.84%

T. Rowe Price Associates, Inc.

Star Investors

12.76M

+1.69%

BlackRock Institutional Trust Company, N.A.

13.00M

-1.29%

Baker Bros. Advisors LP

5.38M

+7.47%

Capital International Investors

7.20M

+1.14%

Fidelity Management & Research Company LLC

3.34M

-28.48%

State Street Global Advisors (US)

5.75M

-5.88%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.83, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Insmed Inc

INSM

7.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.